Vivos TherapeuticsVVOS
13F holders, Q2 2025 (June 30)19holders −2
3new positions
4sold out
$3.16avg. 13F price*
At the end of Q2 2025, 19 institutions reported holding Vivos Therapeutics Inc. (VVOS) in their 13F filings, down 2 from Q1 2025. 3 opened new positions and 4 sold out. The largest holders were UBS Group AG ($451K), B. Riley Wealth Advisors, Inc. ($220K) and Geode Capital Management, LLC ($183K).
- Company
- Vivos Therapeutics Inc.
- CUSIP
- 92859E207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $67K |
| Exits | 4 | $141K |
All 13F filers, Q1 2025 → Q2 2025: 170,174 shares bought and 67,815 shares sold, net +102,359 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| UBS Group AG | 0.00% | Add +7499.8% | 142,801 | $451K |
| B. Riley Wealth Advisors, Inc. | 0.01% | No change | 69,531 | $220K |
| Geode Capital Management, LLC | 0.00% | Add +1.0% | 57,902 | $183K |
| Vanguard Group Inc. | 0.00% | No change | 42,634 | $135K |
| Commonwealth Equity Services, LLC | 0.00% | Add +20.6% | 41,000 | $130K |
| XTX Topco Ltd | 0.00% | New | 20,528 | $65K |
| Northern Trust Corp. | 0.00% | No change | 12,511 | $40K |
| State Street Corp. | 0.00% | No change | 11,822 | $37K |
| Morgan Stanley | 0.00% | Reduce -18.9% | 1,065 | $3K |
| Osaic Holdings, Inc. | 0.00% | Add +296.5% | 793 | $3K |
| Signaturefd, LLC | 0.00% | No change | 547 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 497 | $2K |
| Blue Trust, Inc. | 0.00% | No change | 160 | $506 |
| Bank of America Corp. | 0.00% | Add +5.4% | 137 | $433 |
| Kozak & Associates, Inc. | 0.00% | No change | 49 | $294 |
| Raymond James Financial Inc. | 0.00% | New | 74 | $234 |
| Global Retirement Partners, LLC | 0.00% | — | 23 | $73 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 8 | $25 |
| Royal Bank of Canada | 0.00% | Reduce -100.0% | 4 | $0 |
"% of holder's portfolio" is VVOS's weight in each manager's 13F, not the share of Vivos Therapeutics Inc. the manager owns.